Limits...
A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma.

West SK, Bailey R, Munoz B, Edwards T, Mkocha H, Gaydos C, Lietman T, Porco T, Mabey D, Quinn TC - PLoS Negl Trop Dis (2013)

Bottom Line: There was no difference if analyzed using coverage as a continuous variable.In communities that had pre-treatment prevalence of follicular trachoma of 20% or greater, there is no evidence that MDA can be stopped before 3 annual rounds, even with high coverage.Increasing coverage in children above 90% does not appear to confer additional benefit.

View Article: PubMed Central - PubMed

Affiliation: Dana Center for Preventive Ophthalmology, Johns Hopkins University, Baltimore, Maryland, USA. shwest@jhmi.edu

ABSTRACT

Background: The World Health Organization recommends at least 3 annual antibiotic mass drug administrations (MDA) where the prevalence of trachoma is > 10% in children ages 1-9 years, with coverage at least at 80%. However, the additional value of higher coverage targeted at children with multiple rounds is unknown.

Trial design: 2 × 2 factorial community randomized, double blind, trial.

Trial methods: 32 communities with prevalence of trachoma ≥ 20% were randomized to: annual MDA aiming for coverage of children between 80%-90% (usual target) versus aiming for coverag e> 90% (enhanced target); and to: MDA for three years versus a rule of cessation of MDA early if the estimated prevalence of ocular C. trachomatis infection was less than 5%. The primary outcome was the community prevalence of infection with C. trachomatis at 36 months.

Results: Over the trial's course, no community met the MDA cessation rule, so all communities had the full 3 rounds of MDA. At 36 months, there was no significant difference in the prevalence of infection, 4.0 versus 5.4 (mean adjusted difference  = 1.4%, 95% CI  =  -1.0% to 3.8%), nor in the prevalence of trachoma, 6.1 versus 9.0 (mean adjusted difference  =  2.6%, 95% CI  =  -0.3% to 5.3%) comparing the usual target to the enhanced target group. There was no difference if analyzed using coverage as a continuous variable.

Conclusion: In communities that had pre-treatment prevalence of follicular trachoma of 20% or greater, there is no evidence that MDA can be stopped before 3 annual rounds, even with high coverage. Increasing coverage in children above 90% does not appear to confer additional benefit.

Show MeSH

Related in: MedlinePlus

Prevalence of C.trachomatis Infection over time by Coverage Arm.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3757067&req=5

pntd-0002415-g002: Prevalence of C.trachomatis Infection over time by Coverage Arm.

Mentions: The baseline prevalence of infection with C. trachomatis was not different between the two coverage groups, 20.1% and 23.8% respectively (Figure 2). There was a decline in infection from baseline to 36 months in both the usual target group and the enhanced coverage group. At 36 months (one year after the third MDA), the prevalence of infection was 4.0% in the usual target group and 5.4% in the enhanced target group, with an adjusted difference of 1.4% (95% Confidence Interval (CI) = −1.0% to 3.8%).


A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma.

West SK, Bailey R, Munoz B, Edwards T, Mkocha H, Gaydos C, Lietman T, Porco T, Mabey D, Quinn TC - PLoS Negl Trop Dis (2013)

Prevalence of C.trachomatis Infection over time by Coverage Arm.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3757067&req=5

pntd-0002415-g002: Prevalence of C.trachomatis Infection over time by Coverage Arm.
Mentions: The baseline prevalence of infection with C. trachomatis was not different between the two coverage groups, 20.1% and 23.8% respectively (Figure 2). There was a decline in infection from baseline to 36 months in both the usual target group and the enhanced coverage group. At 36 months (one year after the third MDA), the prevalence of infection was 4.0% in the usual target group and 5.4% in the enhanced target group, with an adjusted difference of 1.4% (95% Confidence Interval (CI) = −1.0% to 3.8%).

Bottom Line: There was no difference if analyzed using coverage as a continuous variable.In communities that had pre-treatment prevalence of follicular trachoma of 20% or greater, there is no evidence that MDA can be stopped before 3 annual rounds, even with high coverage.Increasing coverage in children above 90% does not appear to confer additional benefit.

View Article: PubMed Central - PubMed

Affiliation: Dana Center for Preventive Ophthalmology, Johns Hopkins University, Baltimore, Maryland, USA. shwest@jhmi.edu

ABSTRACT

Background: The World Health Organization recommends at least 3 annual antibiotic mass drug administrations (MDA) where the prevalence of trachoma is > 10% in children ages 1-9 years, with coverage at least at 80%. However, the additional value of higher coverage targeted at children with multiple rounds is unknown.

Trial design: 2 × 2 factorial community randomized, double blind, trial.

Trial methods: 32 communities with prevalence of trachoma ≥ 20% were randomized to: annual MDA aiming for coverage of children between 80%-90% (usual target) versus aiming for coverag e> 90% (enhanced target); and to: MDA for three years versus a rule of cessation of MDA early if the estimated prevalence of ocular C. trachomatis infection was less than 5%. The primary outcome was the community prevalence of infection with C. trachomatis at 36 months.

Results: Over the trial's course, no community met the MDA cessation rule, so all communities had the full 3 rounds of MDA. At 36 months, there was no significant difference in the prevalence of infection, 4.0 versus 5.4 (mean adjusted difference  = 1.4%, 95% CI  =  -1.0% to 3.8%), nor in the prevalence of trachoma, 6.1 versus 9.0 (mean adjusted difference  =  2.6%, 95% CI  =  -0.3% to 5.3%) comparing the usual target to the enhanced target group. There was no difference if analyzed using coverage as a continuous variable.

Conclusion: In communities that had pre-treatment prevalence of follicular trachoma of 20% or greater, there is no evidence that MDA can be stopped before 3 annual rounds, even with high coverage. Increasing coverage in children above 90% does not appear to confer additional benefit.

Show MeSH
Related in: MedlinePlus